The Glycaemia Outcomes of Metformin with Add-on Vildagliptin or Sitagliptin in T2 Diabetes Mellitus
Introduction:
T2DM is a global health concern that requires effective glycemic management to reduce complications. While DPP-4 inhibitors such as vildagliptin and sitagliptin are widely used with metformin, few studies have compared their efficacy in lowering plasma glucose levels. This study aims to address this gap by evaluating the effectiveness of these combinations in glycemic control.
Methods:
A comparative observational study on 172 Patients with T2DM (≥30 years) was done with comorbidities like hypertension, dyslipidemia, and obesity. Inclusion required lab data (FBG, PLBS, HbA1c, Cr, TG) and consent, while exclusions included T1DM, gestational diabetes, insulin therapy, alcohol
use, and emergencies. Primary (HbA1c) and secondary (Cr, TG) outcomes were assessed. Results and Conclusion: The study showed that adding vildagliptin or sitagliptin to metformin significantly improved glycemia control in T2DM
over six months. Both combinations effectively reduced FBS, PLBS, HbA1c, and TG without affecting renal function. In this cohort, patients receiving vildagliptin + metformin showed a greater reduction in blood glucose levels than those receiving sitagliptin + metformin.
Keywords: T2DM, Metformin, Vildagliptin, Sitagliptin, Glycemia control, HbA1C, DPP-4inhibitor
